Skip to content
naulon
Get started

Not checked for notices yet.

Trends and challenges of AAV-delivered gene editing therapeutics for CNS disorders: Implications for neurodegenerative disease

Boris Kantor, Bernadette O'Donovan, Ornit Chiba-Falek

Molecular Therapy: Nucleic Acids · 2025

doi:10.1016/j.omtn.2025.102635

References 250

  1. 1.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  2. 2.
    Adeno-associated virus: from defective virus to effective vector · 2005
    No notice
  3. 3.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  4. 4.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  5. 5.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  6. 6.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  7. 7.
    Development of an intein-mediated split–Cas9 system for gene therapy · 2015
    No notice
  8. 8.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  9. 9.
    Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons · 2015
    No notice
  10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  11. 11.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  14. 14.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  16. 16.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  19. 19.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  20. 20.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  21. 21.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  22. 22.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  23. 23.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  24. 24.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  25. 25.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  26. 26.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  27. 27.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  28. 28.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  29. 29.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  30. 30.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  31. 31.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  32. 32.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  33. 33.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  34. 34.
    α-Synuclein Suppression by Targeted Small Interfering RNA in the Primate Substantia Nigra · 2010
    No notice
  35. 35.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  36. 36.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  37. 37.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  38. 38.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  39. 39.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  40. 40.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  41. 41.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  42. 42.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  43. 43.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  44. 44.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  45. 45.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  46. 46.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  47. 47.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  48. 48.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  49. 49.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  50. 50.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  51. 51.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  52. 52.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  53. 53.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  54. 54.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  55. 55.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  56. 56.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  57. 57.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  58. 58.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  59. 59.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  60. 60.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  61. 61.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  62. 62.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  63. 63.
    SNCA Triplication Parkinson's Patient's iPSC-derived DA Neurons Accumulate α-Synuclein and Are Susceptible to Oxidative Stress · 2011
    No notice
  64. 64.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  65. 65.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  66. 66.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  67. 67.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  68. 68.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  69. 69.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  70. 70.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  71. 71.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  72. 72.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  73. 73.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  74. 74.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  75. 75.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  76. 76.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  77. 77.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  78. 78.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  79. 79.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  80. 80.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  81. 81.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  82. 82.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  83. 83.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  84. 84.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  85. 85.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  86. 86.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  87. 87.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  88. 88.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  89. 89.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  90. 90.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  91. 91.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  92. 92.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  93. 93.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  94. 94.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  95. 95.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  96. 96.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  97. 97.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  98. 98.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  99. 99.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  100. 100.
    CpG Demethylation Enhances Alpha-Synuclein Expression and Affects the Pathogenesis of Parkinson's Disease · 2010
    No notice
  101. 101.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  102. 102.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  103. 103.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  104. 104.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  105. 105.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  106. 106.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  107. 107.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  108. 108.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  109. 109.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  110. 110.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  111. 111.
    Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies · 2014
    No notice
  112. 112.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  113. 113.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  114. 114.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  115. 115.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  116. 116.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  117. 117.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  118. 118.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  119. 119.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  120. 120.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  121. 121.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  122. 122.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  123. 123.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  124. 124.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  125. 125.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  126. 126.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  127. 127.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  128. 128.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  129. 129.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  130. 130.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  131. 131.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  132. 132.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  133. 133.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  134. 134.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  135. 135.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  136. 136.
    A brain microvasculature endothelial cell‐specific viral vector with the potential to treat neurovascular and neurological diseases · 2016
    No notice
  137. 137.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  138. 138.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  139. 139.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  140. 140.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  141. 141.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  142. 142.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  143. 143.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  144. 144.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  145. 145.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  146. 146.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  147. 147.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  148. 148.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  149. 149.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  150. 150.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  151. 151.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  152. 152.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  153. 153.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  154. 154.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  155. 155.
    CRISPR/Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer’s PSEN2 N141I neurons · 2017
    No notice
  156. 156.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  157. 157.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  158. 158.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  159. 159.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  160. 160.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  161. 161.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  162. 162.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  163. 163.
    RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors · 2018
    No notice
  164. 164.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  165. 165.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  166. 166.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  167. 167.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  168. 168.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  169. 169.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  170. 170.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  171. 171.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  172. 172.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  173. 173.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  174. 174.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  175. 175.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  176. 176.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  177. 177.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  178. 178.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  179. 179.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  180. 180.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  181. 181.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  182. 182.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  183. 183.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  184. 184.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  185. 185.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  186. 186.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  187. 187.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  188. 188.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  189. 189.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  190. 190.
    Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria · 2020
    No notice
  191. 191.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  192. 192.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  193. 193.
    APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease · 2020
    No notice
  194. 194.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  195. 195.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  196. 196.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  197. 197.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  198. 198.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  199. 199.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  200. 200.
    Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice · 2021
    No notice
  201. 201.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  202. 202.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  203. 203.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  204. 204.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  205. 205.
    Transposon-associated TnpB is a programmable RNA-guided DNA endonuclease · 2021
    No notice
  206. 206.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  207. 207.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  208. 208.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  209. 209.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  210. 210.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  211. 211.
    Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings · 2022
    No notice
  212. 212.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  213. 213.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  214. 214.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  215. 215.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  216. 216.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  217. 217.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  218. 218.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  219. 219.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  220. 220.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  221. 221.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  222. 222.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  223. 223.
    Various AAV Serotypes and Their Applications in Gene Therapy: An Overview · 2023
    No notice
  224. 224.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  225. 225.
    Efficient prime editing in mouse brain, liver and heart with dual AAVs · 2023
    No notice
  226. 226.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  227. 227.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  228. 228.
    Fanzor is a eukaryotic programmable RNA-guided endonuclease · 2023
    No notice
  229. 229.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  230. 230.
    Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain · 2023
    No notice
  231. 231.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  232. 232.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  233. 233.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  234. 234.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  235. 235.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  236. 236.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  237. 237.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  238. 238.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  239. 239.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  240. 240.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  241. 241.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  242. 242.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  243. 243.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  244. 244.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  245. 245.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  246. 246.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  247. 247.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  248. 248.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  249. 249.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  250. 250.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.